

DAFTAR PUSTAKA

- Alexis AF and Blackcloud P. (2014). Psoriasis in skin of color: epidemiology, genetic, clinical presentation, and treatment nuances. *J Clin Aesthet Dermatol*, 7(11), 16-24.
- Amr KS, Wehshay AH, ElHadidi HH, et al. (2010). A Pilot study of HLA-Cw6 association with Egyptian Psoriasis Patient. *Res J Med Sci*, 5(1), 25-29.
- Atasoy M, Pirim I, Bayrak OF, et al. (2006). Association of HLA class I and class II alleles with psoriasis vulgaris in Turkish population : influence of Type I and Type II psoriasis. *Saudi Med J*, 27(3), 373-6.
- Aydin, S. (2015). A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. *Pept*, 72, 4-15.
- Biral, A., Magalhaes, R., Wastowski, I., Simoes, R., Donadi, E., Simoes, A., . . . Kraemer, M. (2006). Association of HLA-A,-B,-C genes and TNF microsatellite polymorphism with psoriasis vulgaris: a study of genetic risk in Brazilian patients. *Eur J Dermatol*, 16(5), 523-529.
- Boham, M. P., Suling, P. L., & Pandaleke, H. E. (2016). Profil psoriasis di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. RD Kandou Manado periode Januari 2013–Desember 2015. *e-CliniC*, 4(2).
- Brandon, A., Mufti, A., & Sibbald, R. G. (2019). Diagnosis and management of itaneous psoriasis: a review. *Adv Skin Wound Care*, 32(2), 58-69.



Burden, A. D., & Kirby, B. (2016). Psoriasis and Related Disorders. In C. Griffiths, J. Barker, T. Bleiker, R. Chalmers, & D. Creamer (Eds.), *Rook's Textbook of Dermatology* (9th ed., Vol. 2, pp. 1133-1180). Oxford: John Wiley & Sons.

Burlando, M., Russo, R., Clapasson, A., Carmisciano, L., Stecca, A., Cozzani, E., & Parodi, A. (2020). The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis. *J Clin Med*, 9(10), 3140.

Chandra A, Lahiri A, Senapati S et al. (2016) Increased risk of psoriasis due to combined effect of HLA Cw-6 and LC3 risk alleles in Indian Population. *Sci Rep* 6:24059

Chen, L., & Tsai, T. F. (2018). HLA-Cw6 and psoriasis. *Br J Dermatol*, 178(4), 854-862.

Chen, W., Zhou, X., & Zhu, W. (2019). Trace elements homeostatic imbalance in psoriasis: a meta-analysis. *Biol Trace Elem Res*, 191(2), 313-322.

Dalmas E, Venteclef N, Caer C. (2014). T-cell derived IL-22 Amplifies IL-1β driven inflammation in human adipose tissue: relevance to obesity and Type 2 Diabetes. *Diabetes* 63(6):1966-1977

Dominguez, P., Han, J., Li, T., Ascherio, A., & Qureshi, A. (2013). Depression and the risk of psoriasis in US women. *J Eur Acad Dermatol Venereol*, 27(9), 1163-1167.



, J. A., Hanash, A. M., & van den Brink, M. R. (2015). Interleukin-22: immunobiology and pathology. *Annu Rev Immunol*, 33, 747-785.

Elder JT, Nair RP, Gao SW, et al. (1994) The Genetics of Psoriasis. *Archives of Dermatology* 130(2), 216.

Enamandram, M., & Kimball, A. B. (2013). Psoriasis epidemiology: the interplay of genes and the environment. *J Invest Dermatol*, 133(2), 287-289.

Fleming P, Kraft J, Gulliver WP, et al. (2015). The relationship of obesity with the severity of psoriasis: a systematic review. *J Cutan Med*, 19(5), 450-456.

Ghasemi, A., Zahediasl, S., Hosseini-Esfahani, F., & Azizi, F. (2012). Reference values for serum zinc concentration and prevalence of zinc deficiency in adult Iranian subjects. *Biol Trace Elem Res*, 149(3), 307-314.

Gudjonsson, J. E., & Elder, J. T. (2019). Psoriasis. In S. Kang, M. Amagai, A. L. Bruckner, A. H. Enk, D. J. Margolis, A. J. McMichael, & J. S. Orringer (Eds.), *Fitzpatrick's Dermatology* (9th ed., Vol. 1, pp. 457-497). New York: McGraw-Hill Education.

Gudjonsson J, Karason A, Anrondottir AA et al. (2002). HLA-Cw6 positive and HLA-Cw6 negative patients with psoriasis vulgaris have distinct clinical features. *J Invest Dermatol*, 118(2), 362-365.

Gudjonsson JE, Johnston A, Sigmundsdottir H. (2004) Immunopathogenetic mechanism in psoriasis. *Clin Exp Immunol*, 135(1):1-8.

Gupta, R., Debbaneh, M. G., & Liao, W. (2014). Genetic epidemiology of psoriasis. *Curr Dermatol Rep*, 3(1), 61-78.

Hagg D, Sundstrom A, Eriksson M, et al. (2017). Severity of Psoriasis Differs between Men and Women: A Study of Clinical Outcome Measure PASI



Index in 5438 Swedish Register Patient. *Am J Clin Dermatol*, 18(4), 583-590.

Hanani, N. K., Ervianti, E., & Rahniayu, A. (2020). Clinical Profile of Psoriasis Vulgaris at Soetomo General Hospital, Surabaya. *Health Notions*, 4(9), 282-289.

Harden, J. L., Krueger, J. G., & Bowcock, A. M. (2015). The immunogenetics of psoriasis: a comprehensive review. *J Autoimmun*, 64, 66-73.

Hendawy GR, Slama AA, Gaber MA, et al. (2019). Study of interleukin-22 in patients with psoriasis in Menoufia University. *Menoufia Med J*, 29(4), 818-825.

Herder, C., Kannenberg, J. M., Carstensen-Kirberg, M., Huth, C., Meisinger, C., Koenig, W., Peters, A., Rathmann, W., Roden, M., & Thorand, B. (2017). Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. *Cardiovascular diabetology*, 16(1), 17. <https://doi.org/10.1186/s12933-017-0498-6>

Hirata, J., Hirota, T., Ozeki, T., Kanai, M., Sudo, T., Tanaka, T., . . . Mushiroda, T. (2018). Variants at HLA-A, HLA-C, and HLA-DQB1 confer risk of psoriasis vulgaris in Japanese. *J Investig Dermatol*, 138(3), 542-548.

Hofny, E. R., Morsy, H., Hasaball, A., Twisy, H.,. (2017). Serum level of interleukin-22 in patients with psoriasis and its correlation with disease severity. *J of Curr Med Research and Prac*, 2(2), 133-135.

, Rivero E, Rodriguez LA. (2007). Incidence and Risk Factors for Psoriasis in the General Population. *Arch Dermatol*, 143(12), 1559-1565.



- Johnston, A., & Gudjonsson, J. E. (2014). 22 again: IL-22 as a risk gene and important mediator in psoriasis. *J Invest Dermatol*, 134(6), 1501-1503.
- Kerkhof, P. C. M. v. d., & Nestlé, F. O. (2018). Psoriasis. In J. L. Bolognia, J. V. Schaffer, & L. Cerroni (Eds.), *Dermatology* (4th ed., pp. 138-160). China: Elsevier.
- Kogan, S., Sood, A., & Garnick, M. S. (2017). Zinc and wound healing: a review of zinc physiology and clinical applications. *Wounds*, 29(4), 102-106.
- KS, S. L., Darwin, E., Jacob, T. N. A., & Tjong, D. H. (2019). The relationship between human leukocyte antigen-cw6 allele and psoriasis vulgaris. *Dermatol Rep*, 11(s1).
- Lee, E. B., Wu, K. K., Lee, M. P., Bhutani, T., & Wu, J. J. (2018). Psoriasis risk factors and triggers. *Cutis*, 102(5S), 18-20.
- Lei, L., Su, J., Chen, J., Chen, W., Chen, X., & Peng, C. (2019). Abnormal serum copper and zinc levels in patients with psoriasis: A meta-analysis. *Indian J Dermatol*, 64(3), 224-230.
- Llamas-Velasco, M., De la Cueva, P., Notario, J., Martínez-Pilar, L., Martorell, A., & Moreno-Ramírez, D. (2017). Moderate psoriasis: a proposed definition. *Actas Dermosifiliogr*, 108(10), 911-917.
- Mabuchi, T., Ota, T., Manabe, Y., Ikoma, N., Ozawa, A., Terui, T., . . . Oka, A. (2014). HLA-C* 12: 02 is a susceptibility factor in late-onset type of psoriasis in Japanese. *J Dermatol*, 41(8), 697-704.



es, R. F., Biral, A. C., Pancoto, J. A. T., Donadi, E. A., Mendes-Júnior, C., Magna, L. A., & Kraemer, M. H. (2010). Human leukocyte antigen

(HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha-238 and-308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. *Int J Dermatol*, 49(10), 1133-1140.

Manolache L, Petrescu-Seceleanu, Benea V. (2010). Life events involvement in psoriasis onset/recurrence. *Int J Dermatol*, 49(6), 636-641.

Mikkawy DE, Sadek ME, Badawy ME, et al. (2020) Circulating level of interleukin-6 in relation to body mass indices and lipid profile in Egyptian adults with overweight and obesity. *Egyptian Rheumatology and Rehabilitation*, 47(7)

Naldi, L. (2013). Risk factors for psoriasis. *Curr Dermatol Rep*, 2(1), 58-65.

Nikamo, P., Cheuk, S., Lysell, J., Enerbäck, C., Bergh, K., Landén, N. X., . . . Ståhle, M. (2014). Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells. *J Invest Dermatol*, 134(6), 1535-1541.

Nogralles, K. E., Davidovici, B., & Krueger, J. G. (2010). *New insights in the immunologic basis of psoriasis*. Paper presented at the Semin Cutan Med Surg.

Norden A, Rekhtman S, Strunk A et al. Risk of psoriasis according to body mass index: a retrospective cohort analysis. <https://doi.org/10.1016/j.jaad.2021.06.012>



Y., Kawamura, T., & Shimada, S. (2016). Zinc and skin biology. *Arch Biochem Biophys*, 611, 113-119.

Ogawa, Y., Kinoshita, M., Shimada, S., & Kawamura, T. (2018a). Zinc and skin disorders. *Nutrients*, 10(2), 199.

Ogawa, Y., Kinoshita, M., Shimada, S., & Kawamura, T. (2018b). Zinc in keratinocytes and langerhans cells: Relevance to the epidermal homeostasis. *J Immunol Res*, 2018.

Oji, V., & Luger, T. A. (2015). The skin in psoriasis: assessment and challenges. *Clin Exp Rheumatol*, 33(5 Suppl 93), S14-19.

Onsun, N., Pirmir, S., Ozkaya, D., Çelik, Ş., Rezvani, A., Cengiz, F. P., & Kekik, C. (2019). The HLA-Cw12 Allele Is an Important Susceptibility Allele for Psoriasis and Is Associated with Resistant Psoriasis in the Turkish Population. *Sci World J*, 2019.

Papautsky, I., Shen, L., Hagen, J., & Stone, M. (2016). Method and system for analyzing a colorimetric assay: Google Patents.

Papp KA, Ginadecki R, Becker J, et al. (2021). Psoriasis prevalence and severity by expert elicitation. *Dermatol Ther*, 11, 1053-1064.

Prans, E., Kingo, K., Traks, T., Silm, H., Vasar, E., & Kõks, S. (2013). Copy number variations in IL22 gene are associated with Psoriasis vulgaris. *Hum Immunol*, 74(6), 792-795.

Qureshi AA, Hyin KC, Setty AR. (2009). Psoriasis and the Risk of Diabetes and Hypertension. *Arch Dermatol*, 145(4), 379-382.

Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. *Int J Mol Sci*, 20(6), 1475.



Riveira-Munoz, E., He, S.-M., Escaramís, G., Stuart, P. E., Hüffmeier, U., Lee, C., . . . Liao, W. (2011). Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. *J Invest Dermatol*, 131(5), 1105-1109.

Saeki, H., Hirota, T., Nakagawa, H., Tsunemi, Y., Kato, T., Shibata, S., . . . Miyatake, A. (2013). Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population. *J Dermatol Sci*, 71(2), 148-150.

Schonmann Y, Ashcroft DM, Iskandar IYK, et al. Incidence and prevalence of psoriasis in Israel between 2011 and 2017. *JEADV*, 33(11), 2075-2081.

Shafiyah, N., Diba, S., & Ikhsan, D. S. (2019). *Insidensi Psoriasis Vulgaris di Poliklinik Dermatologi dan Venereologi RSUP Dr. Mohammad Hoesin Palembang Periode 2014–2018*. Sriwijaya University.

Shankarkumar, U. (2012). HLA C allele associations in Mumbai psoriasis patients. *Int J Hum Genet*, 12(1), 41-44.

Shimauchi, T., Hirakawa, S., Suzuki, T., Yasuma, A., Majima, Y., Tatsuno, K., . . . Tokura, Y. (2013). Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. *J Dermatol*, 40(10), 805-812.

Sinha, S., Kar, K., Dasgupta, A., Basu, S., & Sen, S. (2016). Correlation of Serum TSH with TSH in hyperthyroidism. *Asian J Med Sci*, 7(1), 66-69. doi:<https://doi.org/10.3126/ajms.v7i1.12895>



Sobhan M, Farshchian M. (2017). Association between body mass index and severity of psoriasis. *Clin Cosmet Investig Dermatol*, 10, 492-498.

Sri Lestari KS, (2019). *Dermatol Rep*, 11(1), 8054.

Sylviningrum T, Putranti IO, Sari OP. (2019) Association between HLA Cw-6 allele expression and characteristics of Javanese ethnic psoriasis patient in Indonesia. *MJI*, 28(4)

Thorleifsdottir, R. H., Sigurdardottir, S. L., Sigurgeirsson, B., Olafsson, J. H., Petersen, H., Sigurdsson, M. I., . . . Valdimarsson, H. (2016). HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series. *J Am Acad Dermatol*, 75(5), 889-896.

Trettel A, Spehr C, Korber A., et al. (2017). The impact of age on psoriasis healthcare in Germany. *JEAD*, 31(5), 870-875.

Tsukada, M. (2012). Probe set and method for identifying HLA allele: Google Patents.

Van Vugt, L., van den Reek, J., Coenen, M., & de Jong, E. (2018). A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. *Br J Dermatol*, 178(1), 86-94.

Vasili, E., Vargu, M., Burazeri, G., Hysa, K., Cano, E., & Bezati, B. (2012). Psoriasis and Diabetes *Inflammatory Diseases-Immunopathology, Clinical and Pharmacological Bases*: IntechOpen.




- Wawrzyski, B., Pietrzak, A., Grywalska, E., Krasowska, D., Chodorowska, G., & Roliński, J. (2019). Interleukin-22 and its correlation with disease activity in plaque psoriasis. *Arch Immunol Ther Exp*, 67(2), 103-108.
- West, J., Ogston, S., Berg, J., Palmer, C., Fleming, C., Kumar, V., & Foerster, J. (2017). HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. *Clin Exp Dermatol*, 42(6), 651-655.
- Widaty, S., Soebono, H., Nilasari, H., Listiawan, M. Y., Siswati, A. S., Triwahyudi, D., . . . Menaldi, S. L. (2017). *Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia*. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI).
- Yeung H, Takeshita J, Mehta NN., et al. (2013). Psoriasis severity and the prevalence of major medical comorbidities: a population based study *JAMA Dermatol*, 1499(10), 1173-1179.



LAMPIRAN

Lampiran Etik



REKOMENDASI PERSETUJUAN ETIK

Nomor : 345/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 27 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik:

No Protokol	UH21050292	No Sponsor Protokol	
Peneliti Utama	dr. Timothy Yusuf Sangian	Sponsor	
Judul Peneliti	Perbandingan Antara Alel HLA Cw-6 dan Zink Terhadap Kadar Interleukin 22 pada Pasien Psoriasis Vulgaris dengan Kontrol		
No Versi Protokol	2	Tanggal Versi	24 Mei 2021
No Versi PSP	2	Tanggal Versi	24 Mei 2021
Tempat Penelitian	RS Universitas Hasanuddin dan RS Afiliasi, RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 27 Mei 2021 sampai 27 Mei 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran Alat dan Badan

